Y-mAbs Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Y-mAbs Therapeutics

09/08/2024 19:34

* Y-mAbs Therapeutics Inc  YMAB.OQ   YMAB.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 12
for the period ending June 30 2024
    * The New York City-based  company is expected to report a
10.9% increase in revenue to $23.019 million from $20.75 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc
is for
a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $22.00​, above​ its last closing price
of $11.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.14       -0.14      -0.15     Missed  -10.5
 Dec. 31 2024  -0.20       -0.20      -0.02     Beat    90.1
 Sep. 30 2023  -0.18       -0.19      -0.18     Beat    3.7​
 Jan. 1 0001   -0.24       -0.24      -0.14     Beat    42.1
 ​​Mar.        -0.32       -0.32      -0.15     Beat    52.9
 31 2023                                                
 Dec. 31 2022  -0.44       -0.46      0.03      Beat    106.6​
 Sep. 30 2022  -0.71       -0.71      -0.63     Beat    11.3
 Jun. 30 2022  -0.67       -0.67      -0.94     Missed  -41.2
 This summary was machine generated August 9 at 18:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)